Title |
Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment
|
---|---|
Published in |
OncoTargets and therapy, May 2012
|
DOI | 10.2147/ott.s30609 |
Pubmed ID | |
Authors |
Phuc Van Pham, Ngoc Bich Vu, Thuy Thanh Duong, Tam Thanh Nguyen, Nhung Hai Truong, Nhan Lu Chinh Phan, Tue Gia Vuong, Viet Quoc Pham, Hoang Minh Nguyen, Kha The Nguyen, Nhung Thi Nguyen, Khue Gia Nguyen, Lam Tan Khat, Dong Van Le, Kiet Dinh Truong, Ngoc Kim Phan |
Abstract |
Breast cancer stem cells with a CD44(+)CD24(-) phenotype are the origin of breast tumors. Strong CD44 expression in this population indicates its important role in maintaining the stem cell phenotype. Previous studies show that CD44 down-regulation causes CD44(+)CD24(-) breast cancer stem cells to differentiate into non-stem cells that are sensitive to antitumor drugs and lose many characteristics of the original cells. In this study, we determined tumor suppression in non-obese severe combined immunodeficiency mice using CD44 shRNA therapy combined with doxorubicin treatment. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Poland | 1 | 5% |
Unknown | 21 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 5 | 23% |
Researcher | 5 | 23% |
Student > Postgraduate | 3 | 14% |
Other | 2 | 9% |
Student > Master | 1 | 5% |
Other | 2 | 9% |
Unknown | 4 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 6 | 27% |
Medicine and Dentistry | 5 | 23% |
Biochemistry, Genetics and Molecular Biology | 4 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 9% |
Chemical Engineering | 1 | 5% |
Other | 2 | 9% |
Unknown | 2 | 9% |